Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26672690 | 0.85 | CRBN (0.34) | KDM4ESMN1; SMN2MAPTNPSR1LMNA | |
| SCHEMBL26672672 | 0.85 | KDM4E (0.32) | KDM4ESMN1; SMN2 | |
| SCHEMBL26672573 | 0.84 | KDM4E (0.35) | KDM4ESMN1; SMN2MAPTNPSR1LMNA | |
| SCHEMBL26672844 | 0.80 | — | — | |
| SCHEMBL22200929 | 0.79 | LMNA (0.42) | KDM4EMAPTNPSR1LMNARAB9A | |
| SCHEMBL37106799 | 0.79 | LMNA (0.42) | KDM4EMAPTNPSR1LMNARAB9A | |
| SCHEMBL7165490 | 0.79 | LMNA (0.42) | KDM4EMAPTNPSR1LMNARAB9A | |
| SCHEMBL30221837 | 0.79 | BRD3 (0.31) | KDM4EMAPTLMNA | |
| SCHEMBL30221744 | 0.79 | BRD3 (0.31) | KDM4EMAPTLMNA | |
| SCHEMBL7655413 | 0.79 | KDM4E (0.35) | KDM4ESMN1; SMN2MAPTNPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416270-A1 | NOVEL CAMPTOTHECIN DERIVATIVE, COMPOSITION COMPRISING SAME AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-12-28 | — | — | US | disclosed |
| EP-4265620-A1 | NOVEL CAMPTOTHECIN DERIVATIVE, COMPOSITION CONTAINING SAME, AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-4265620-A1 | NOVEL CAMPTOTHECIN DERIVATIVE, COMPOSITION CONTAINING SAME, AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| CN-116583526-A | Novel camptothecin derivative, composition containing same and use thereof | 微境生物医药科技(上海)有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116253747-A | Novel homocamptothecin derivative, composition containing same and application thereof | 微境生物医药科技(上海)有限公司 | 2023-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416270-A1 | NOVEL CAMPTOTHECIN DERIVATIVE, COMPOSITION COMPRISING SAME AND USE THEREOF | WEE1, WEE2, TOP1 | KDM4E 4388/4885SMN1; SMN2 4653/4885MAPT 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.